中国P站

Rapid diagnostics; Point-Of-Care Testing (POCT); Infectious diseases; Antimicrobial resistance (AMR); Neglected tropical diseases (NTDs); Cancer detection; Microfluidics; Biosensors; Emerging infectious diseases; Respiratory viruses

Introduction

Molecular point-of-care testing (mPOCT) represents a significant advancement in diagnostics for infectious diseases, offering rapid, accurate, and accessible results outside traditional laboratory settings. This approach is transforming disease management by enabling timely interventions, improving patient outcomes, and facilitating disease surveillance, especially in resource-limited areas. Its impact is particularly notable in areas like respiratory infections, sexually transmitted infections, and antimicrobial resistance detection[1] Rapid diagnostic tests (RDTs) play a crucial role in managing neglected tropical diseases (NTDs), especially in endemic regions with limited laboratory infrastructure. This review highlights the availability and performance of various RDTs for different NTDs, emphasizing their potential to facilitate early diagnosis, guide treatment decisions, and support disease elimination efforts. Despite their advantages, challenges remain in terms of sensitivity, specificity, and broad implementation across diverse settings[2] Addressing the global crisis of antimicrobial resistance (AMR) requires rapid and accurate diagnostic tools that can quickly identify resistant pathogens and guide appropriate treatment. Point-of-care diagnostics (POCD) for AMR hold immense promise, offering solutions for rapid detection of resistance genes and phenotypic susceptibility testing directly at the patient's side. Developing robust, user-friendly, and cost-effective POCD platforms is crucial for combating AMR and optimizing antibiotic stewardship[3] The accurate and timely diagnosis of respiratory viral infections is critical for patient management and public health, especially during seasonal epidemics and pandemics. Rapid diagnostic tests for respiratory viruses, including influenza, RSV, and SARS-CoV-2, have evolved significantly, offering quicker results than traditional lab methods. While beneficial for initial screening and triage, understanding their varying sensitivities and specificities is essential for effective clinical application[4] Emerging infectious diseases pose a constant threat to global health, necessitating swift and accurate diagnostic tools. Recent advances in rapid diagnostic platforms, including CRISPR-based assays, lab-on-a-chip technologies, and advanced biosensors, are revolutionizing the response to these outbreaks. These innovations offer enhanced sensitivity, specificity, and portability, promising faster detection and better control strategies for novel pathogens[5] Implementing rapid diagnostic tests (RDTs) in low-resource settings presents unique challenges, including infrastructure limitations, supply chain issues, and the need for robust performance under harsh conditions. Despite these hurdles, RDTs offer immense opportunities to improve healthcare access and outcomes by enabling decentralized testing and quicker treatment decisions. Overcoming these challenges requires innovative design, simplified workflows, and integrated healthcare strategies[6] Multiplexed rapid diagnostic tests (MRDTs) represent a powerful evolution in diagnostics, allowing for the simultaneous detection of multiple pathogens or biomarkers from a single sample. This capability is particularly valuable for syndromic presentations, where several etiologies might be at play. Recent advances in MRDTs improve diagnostic efficiency, reduce turnaround time, and offer a more comprehensive understanding of complex infectious diseases[7] The application of rapid diagnostic tools extends beyond infectious diseases, showing significant promise in early cancer detection and monitoring. Point-of-care (POC) devices for cancer aim to provide quick, non-invasive, and accessible screening, leveraging biomarkers in various bodily fluids. These advancements could revolutionize cancer diagnostics by facilitating early intervention, particularly in settings with limited access to specialized medical facilities[8] Microfluidics technology is at the forefront of developing next-generation rapid diagnostic tools, particularly for global health challenges. These lab-on-a-chip devices offer miniaturization, automation, and high throughput, enabling complex diagnostic assays to be performed with minimal sample volume and reagents. Their potential for low-cost, portable, and rapid diagnostics makes them ideal for decentralized testing in remote or resource-constrained environments[9] The rapid detection of environmental and foodborne pathogens is crucial for ensuring public safety and preventing outbreaks. Innovative rapid diagnostic technologies are transforming food safety monitoring and environmental surveillance by offering quick, sensitive, and specific detection methods. These advancements, including biosensors, immunoassays, and molecular techniques, are vital for maintaining robust public health protection and preventing food contamination[10]

Description

Rapid diagnostic tools are fundamentally transforming disease management across various health sectors. Molecular Point-Of-Care Testing (mPOCT) stands out as a significant advancement in diagnosing infectious diseases, delivering quick, accurate, and accessible results outside traditional lab environments. This innovation improves patient outcomes and strengthens disease surveillance, particularly in resource-limited settings, impacting areas like respiratory infections, sexually transmitted infections, and antimicrobial resistance detection [1]. These rapid diagnostic tests (RDTs) also play a crucial part in addressing neglected tropical diseases (NTDs), especially in endemic regions with limited laboratory infrastructure. They facilitate early diagnosis, guide treatment decisions, and support global elimination efforts [2].

The global crisis of antimicrobial resistance (AMR) demands prompt and precise diagnostic instruments. Point-Of-Care Diagnostics (POCD) for AMR offer immense potential by enabling rapid detection of resistance genes and phenotypic susceptibility testing directly at the patient's bedside. Developing user-friendly and cost-effective POCD platforms is essential for combating AMR and optimizing antibiotic stewardship [3].

Likewise, the accurate and timely diagnosis of respiratory viral infections, including influenza, RSV, and SARS-CoV-2, remains critical for patient care and public health. RDTs offer faster results for initial screening and triage, though understanding their varying sensitivities and specificities is essential for effective clinical application [4]. Beyond known threats, emerging infectious diseases pose a constant global health risk, necessitating swift and precise diagnostic tools. Recent progress in rapid diagnostic platforms, such as CRISPR-based assays, lab-on-a-chip technologies, and advanced biosensors, are revolutionizing the response to these outbreaks by offering enhanced sensitivity, specificity, and portability [5].

Despite their immense benefits, implementing rapid diagnostic tests in low-resource settings faces unique challenges, including infrastructure limitations, supply chain issues, and the demand for reliable performance under difficult conditions. Yet, these tests provide significant opportunities to improve healthcare access and outcomes through decentralized testing and quicker treatment decisions, requiring innovative design and integrated healthcare strategies [6].

Technological advancements are also driving the evolution of diagnostics. Multiplexed rapid diagnostic tests (MRDTs) exemplify this, allowing for simultaneous detection of multiple pathogens or biomarkers from a single sample. This capability is invaluable for syndromic presentations, enhancing diagnostic efficiency and providing a more comprehensive understanding of complex infectious diseases [7]. Microfluidics technology is at the forefront of developing next-generation rapid diagnostic tools, particularly for global health. These lab-on-a-chip devices offer miniaturization, automation, and high throughput, making them ideal for low-cost, portable, and rapid decentralized testing in remote or resource-constrained environments [9]. The utility of rapid diagnostic tools extends beyond infectious diseases, showing significant promise in early cancer detection and monitoring. Point-Of-Care (POC) devices for cancer aim to provide quick, non-invasive, and accessible screening by leveraging biomarkers found in various bodily fluids [8]. Furthermore, the rapid detection of environmental and foodborne pathogens is vital for public safety and outbreak prevention. Innovative rapid diagnostic technologies are transforming food safety monitoring and environmental surveillance, offering quick, sensitive, and specific detection methods through biosensors, immunoassays, and molecular techniques, thereby reinforcing public health protection [10].

Conclusion

Rapid diagnostic tests represent a transformative approach across various healthcare and public health domains. Molecular Point-Of-Care Testing (mPOCT) has significantly advanced diagnostics for infectious diseases, delivering rapid and accurate results outside conventional laboratory settings, improving patient outcomes and disease surveillance in resource-limited areas. This is particularly relevant for respiratory infections, sexually transmitted infections, and antimicrobial resistance detection. Similarly, RDTs are indispensable for managing neglected tropical diseases in endemic regions, enabling early diagnosis and supporting elimination efforts, despite existing challenges in sensitivity and specificity. The global challenge of antimicrobial resistance specifically benefits from Point-Of-Care Diagnostics (POCD), which facilitate swift identification of resistant pathogens and guide appropriate treatment, emphasizing the need for user-friendly and cost-effective platforms. Beyond infectious diseases, these rapid diagnostic tools show promise in early cancer detection and monitoring, with Point-Of-Care devices offering non-invasive screening using biomarkers. Advances in rapid diagnostic platforms, including CRISPR-based assays and lab-on-a-chip technologies, are crucial for responding to emerging infectious diseases, providing enhanced sensitivity and portability. Microfluidics technology further propels the development of next-generation rapid diagnostics for global health, offering miniaturized and automated solutions ideal for decentralized testing. However, implementing RDTs in low-resource settings faces hurdles like infrastructure limitations and supply chain issues, yet they offer significant opportunities for improving healthcare access. Finally, multiplexed rapid diagnostic tests enhance efficiency by detecting multiple pathogens simultaneously, while rapid diagnostic technologies also secure public safety through quick and sensitive detection of environmental and foodborne pathogens, preventing contamination and outbreaks.

References

1. Mitali M, Sumit K, Ankita G (2024 Jan-Mar) .J Global Infect Dis 16:1-13.

   , ,

2. Julius KO, Seth KO, Florence NS (2023 Jul 26) .Diagnostics (Basel) 13:2368.

   , ,

3. Hui Y, Qian W, Qin L (2023 Mar 22) .Biosensors (Basel) 13:367.

   , ,

4. Eleonora L, Rita M, Veronica C (2023 Jan 12) .Viruses 15:161.

   , ,

5. Zohaib A, Rizwan A, Ola FA (2022 Sep 27) .Diagnostics (Basel) 12:2368.

   , ,

6. Shikha S, Neha P, Shivika V (2022 Dec 12) .Front Public Health 10:994038.

   , ,

7. Mohammed YA, Yasmeen A, Samer A (2021 Aug 3) .Biosensors (Basel) 11:260.

   , ,

8. Meenakshi G, Puja S, Subhankar D (2021 Sep 20) .J Transl Med 19:386.

   , ,

9. Naresh K, Prachi A, Jasleen K (2020 Jan-Dec) .Bioengineered 11:1157-1175.

   , ,

10. Chen W, Xiaohan L, Chengjie L (2020 Sep) .Trends Food Sci Technol 103:228-241.

    , ,